PAS
ALXN

Park Avenue Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Park Avenue Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,396
Closed -$440K – 1081
2021
Q2 		$440K Sell
2,396
-313
-12% -$53.7K 0.01% 689
2021
Q1 		$414K Sell
2,709
-1,207
-31% -$187K 0.01% 642
2020
Q4 		$612K Buy
3,916
+235
+6% +$30.2K 0.02% 451
2020
Q3 		$421K Buy
3,681
+101
+3% +$10.9K 0.01% 466
2020
Q2 		$402K Buy
3,580
+495
+16% +$52.6K 0.02% 428
2020
Q1 		$277K Buy
3,085
+811
+36% +$79.6K 0.02% 248
2019
Q4 		$246K Buy
+2,274
New +$243K 0.01% 516

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Park Avenue Securities's ALXN Position: Q3 2021 in Review

Park Avenue Securities sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,396 shares — an estimated $440K sold.

Park Avenue Securities first reported a position in ALXN in Q4 2019 and held it in 7 quarters. The position peaked at $612K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Park Avenue Securities reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Park Avenue Securities sold 2,396 Alexion Pharmaceuticals shares in Q3 2021, an estimated $440K.
  • Park Avenue Securities first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Park Avenue Securities's Alexion Pharmaceuticals position peaked at $612K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Park Avenue Securities's 13F filing for Q3 2021, filed 21 Oct 2021.